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Introduction {#ehf212606-sec-0004}
============

Patients suffering from heart failure (HF) account for nearly 1--2% of the adult population in developed countries, rising up to ≥10% among people above 70 years of age with increasing prevalence due to demographic changes.^.^ [1](#ehf212606-bib-0001){ref-type="ref"}, [2](#ehf212606-bib-0002){ref-type="ref"}, [3](#ehf212606-bib-0003){ref-type="ref"}, [4](#ehf212606-bib-0004){ref-type="ref"} HF patients are mainly categorized into HF with reduced (HFrEF) and preserved ejection fraction (HFpEF) due to different underlying aetiologies, demographics, comorbidities, and response to therapies.^.^ [5](#ehf212606-bib-0005){ref-type="ref"}, [6](#ehf212606-bib-0006){ref-type="ref"} The prevalence of both entities and their prognoses is comparable.[7](#ehf212606-bib-0007){ref-type="ref"} Despite remarkable progress in HF research, we still miss a specific treatment for HFpEF, at the moment the guidelines focus on optimizing the comorbidities.

However, the economic burden of HF treatment increases with its prevalence. Cardiovascular diseases are estimated to cost about \$130 billion in Europe annually with HF as a major matter of expense.[8](#ehf212606-bib-0008){ref-type="ref"} HF cost estimates in the USA amount to \$39.2 billion in direct costs,[9](#ehf212606-bib-0009){ref-type="ref"} which do not include the impact on the economic reduction in work force nor the informal care these patients receive. A key portion of HF direct costs is caused by hospitalization, while \~5% of all hospital admissions in Western countries are due to HF.^.^ [10](#ehf212606-bib-0010){ref-type="ref"}, [11](#ehf212606-bib-0011){ref-type="ref"}, [12](#ehf212606-bib-0012){ref-type="ref"} Projected total medical costs in 2030 will rise up \$53.1 billion, and nearly 80% of these projected expenses are attributed to increased hospitalizations.[13](#ehf212606-bib-0013){ref-type="ref"}, [14](#ehf212606-bib-0014){ref-type="ref"}, [15](#ehf212606-bib-0015){ref-type="ref"} All these details are mainly based on databases from national registries and insurance companies.[16](#ehf212606-bib-0016){ref-type="ref"} These databases underestimate the costs of HF patients systematically because of differently attributed diagnoses for hospitalization due to common comorbidities of HF patients. In particular, HFpEF patients are inadequately represented because of various comorbidities and a systematic neglect due to the absence of direct treatment options.[17](#ehf212606-bib-0017){ref-type="ref"} Based on the recommended guideline treatment for HFrEF patients, monitoring HFrEF costs is easier on a non‐individual‐based approach in registries.

The aldosterone receptor blockade in diastolic HF (aldo‐DHF) study was a randomized, controlled trial investigating the effects of chronic aldosterone receptor blockade in 422 outpatient stable HFpEF patients during a 12‐month follow‐up period.[18](#ehf212606-bib-0018){ref-type="ref"} Its co‐primary endpoints were E/e\' and peakVO~2~.

Thus, in this analysis, we aim to (i) analyse the structure of the costs and to (ii) assess the direct health costs for this stable outpatient HFpEF population. Ultimately, we aim to (iii) evaluate the effect of spironolactone on the overall direct costs and the cost distribution and to (iv) identify predictors for higher costs in subjects based on these findings.

Methods {#ehf212606-sec-0005}
=======

Study design and setting {#ehf212606-sec-0006}
------------------------

The aldo‐DHF trial was a multicentre, randomized, placebo‐controlled, double‐blind study within the framework of the German Competence Network Heart Failure (KNHI) between 2007 and 2012.[19](#ehf212606-bib-0019){ref-type="ref"} The study design and the primary results of the aldo‐DHF trial have been previously published.[18](#ehf212606-bib-0018){ref-type="ref"}, [20](#ehf212606-bib-0020){ref-type="ref"} Briefly, eligible patients were enrolled and randomized to spironolactone 25 mg once daily or matching placebo. The diagnosis of HFpEF was based mainly on the Paulus criteria \[symptomatic HF, left ventricular ejection fraction (LVEF) ≥ 50% at rest and echocardiographic signs of diastolic dysfunction (tissue doppler‐derived E/e\' \> 15 or E/e\' \> 8 in combination with the presence of either elevated N terminal pro brain natriuretic peptide or brain natriuretic peptide or atrial fibrillation)\]^.^ [21](#ehf212606-bib-0021){ref-type="ref"} Ultimately, symptomatic patients with New York Heart Association class II or III, LVEF ≥ 50% at rest, echocardiographic evidence of grade ≥ I diastolic dysfunction or present atrial fibrillation, and peak VO~2~ ≤ 25 mL/kg/min were eligible for participation.[20](#ehf212606-bib-0020){ref-type="ref"} Major exclusion criteria included prior documented LVEF ≤ 40%, significant coronary artery disease, myocardial infarction or coronary artery bypass graft surgery within 3 months, definite or probable pulmonary disease \[vital capacity \< 80% or forced expiratory volume in 1 s \< 80% of reference values on spirometry\], body mass index ≥ 36 kg/m, or serum creatinine \> 1.8 mg/dL. After the baseline examination and the randomization, patients were seen at visits after 1 week and 3, 6, 9, and 12 months. Examination results, questionnaires, and changes of medication were recorded at each visit. The study protocol was reviewed and approved by the institutional review board of each participating centre, and all patients provided written informed consent prior to enrolment. Aldo‐DHF was conducted in accordance with national laws, guidelines for good clinical practice, and the Declaration of Helsinki.

Subject population {#ehf212606-sec-0007}
------------------

We analysed the data of 422 patients. The data collection also consisted of details regarding physician visits, rehabilitation, and hospital admissions as well as the concomitant medication at the screening, the baseline, and the follow‐up visits every 3 months for a year.

Endpoint {#ehf212606-sec-0008}
--------

The main endpoint in focus was defined as the overall direct costs. These direct costs were based on (i) structural costs assessed by the number of general practitioner (GP) and cardiologist visits, number of HF hospitalizations, duration of cardiac rehabilitation, and duration of required nursing care as well as (ii) medication costs assessed by the number of days the medication was taken and the individual composition of medication per day.

Cost parameter assessment {#ehf212606-sec-0009}
-------------------------

We analysed the cost of illness with a bottom‐up‐approach[22](#ehf212606-bib-0022){ref-type="ref"}, [23](#ehf212606-bib-0023){ref-type="ref"} based on the details of every single patient. We considered cardiovascular medication as relevant for our analysis and therefore as distinguishable from other medication. These considered medication included beta‐blocker, angiotensin‐converting enzyme inhibitors, angiotensin II receptor blockers, diuretics, cardiac glycosides, statines, other lipid‐lowering agents, antiarrhythmic agents, calcium channel blocker, anticoagulants, nitrates, oral antidiabetic medication, and insulin and pulmonary medication. For the calculations of the costs due to the concomitant medication, we used the price for the cheapest generic in the largest available package size on the German market in the year 2011 for our calculations.

Regarding outpatient physician visits, we considered visits to GPs, specialists in internal medicine, and cardiologists as relevant for our analysis. Reliable data for costs per physician visit were only available from the year 1999.[24](#ehf212606-bib-0024){ref-type="ref"} Therefore, we adjusted these for inflation and set the year 2011 as the reference point of time.

The direct costs of hospitalization were assessed when the hospitalization reported at the baseline visit for the previous 12 months or any other follow‐up visit was due to HF. The direct economic costs of a hospitalization emerge from both the treatment costs and the infrastructural costs of the health care provider. We used an established approach to assess these costs by including the average HF costs based on diagnosis‐related group statistics from the Federal Statistical Office of Germany and added the infrastructural state funding per day multiplied by the duration of the hospital stay to assess the hospitalization costs.[24](#ehf212606-bib-0024){ref-type="ref"}

Statistical methods {#ehf212606-sec-0010}
-------------------

Study cohort and subgroups are described by absolute and relative frequencies for categorical data, by mean and standard deviation (SD) for symmetric continuous variables and in addition, median and quartiles/interquartile range for skewed continuous variables.

We compared frequencies by χ^2^ test and Fisher\'s exact test. Continuous variables were compared by *t*‐tests for independent samples with Satterthwaite approximation or by Mann--Whitney *U* tests.

For the analysis of both the physician visits and the hospitalizations, we summed up the details at each visit per patient. Medication costs were calculated as a product of daily dosage, price per dosage, and number of days taken.

In searching baseline variables associated with the total direct costs, we built various regression models. After simple linear regression models with variables from *Table* [1](#ehf212606-tbl-0001){ref-type="table"}, we built a multiple regression model and excluded irrelevant variables by backward selection with probabilities for inclusion: p_in = 0.2 and exclusion p_out = 0.05. Final models were built with the variables selected that way to get correct estimates for incidence rate ratios, which were calculated including two‐sided 95% confidence intervals.

###### 

patient characteristics I

  Variable                    Spironolactone *n* (%)   Placebo *n* (%)   *P value*
  --------------------------- ------------------------ ----------------- -----------
  Female                      111 (52)                 110 (53)          0.9150
  CAD                         92 (43)                  78 (37)           0.2188
  Arterial hypertension       197 (92)                 190 (91)          0.5565
  CVD                         23 (11)                  22 (11)           0.9279
  PAD                         7 (3)                    10 (5)            0.4338
  Atrial fibrillation         30 (14)                  36 (17)           0.3746
  Chronotropic incompetence   9 (4)                    16 (8)            0.1356
  NYHA III                    33 (15)                  26 (12)           0.3659
  Hyperlipidemia              130 (61)                 143 (68)          0.1123
  Diabetes mellitus           36 (17)                  34 (16)           0.8611
  sleep apnoea                29 (14)                  21 (10)           0.2569
  COPD                        11 (5)                   3 (1)             0.0535
  Depression                  22 (10)                  25 (12)           0.5939
  Paulus criteria positive    111 (52)                 109 (52)          0.9934

CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CVD, cerebrovascular disease; PAD, peripheral artery disease; Paulus criteria, HFpEF criteria mentioned above.[21](#ehf212606-bib-0021){ref-type="ref"}

Results {#ehf212606-sec-0011}
=======

Subject population {#ehf212606-sec-0012}
------------------

A total of 422 patients were randomly assigned to receive spironolactone (*n* = 213) or matching placebo (*n* = 209) with 12 months of follow‐up. Patients who dropped out were analysed until their dropout. There was no relevant difference in the number of dropouts (9 vs. 13, *P* = 0.22) nor in the baseline characteristics (*Tables* [1](#ehf212606-tbl-0001){ref-type="table"} *and* [2](#ehf212606-tbl-0002){ref-type="table"}) between both groups.

###### 

Patient characteristics II

  Variable                    Spironolactone   Placebo   *P value*                                                      
  --------------------------- ---------------- --------- ----------- ------- ------ ----- ------- ------ ------- ------ ----------
  Age \[years\]               213              66.9      7.7         67.0    12.0   209   66.7    7.5    68.0    11.0   0.8038
  BMI \[kg/m^2^\]             213              28.9      3.6         29.0    5.0    209   28.9    3.6    28.8    5.1    0.9644
  MAP \[mmHg\]                213              97.6      11.4        96.3    16.0   209   98.2    12.2   98.0    14.7   0.5435
  Pulse pressure \[mmHg\]     213              55.8      14.8        54.0    19.0   209   55.8    15.8   55.0    20.0   0.9667
  HR in ECG \[min^−1^\]       213              66.5      13.8        65.0    15.0   208   64.3    11.8   63.0    11.5   *0.0815*
  eGFR \[ml/min/1.73 m^2^\]   211              79.3      19.2        77.7    25.6   208   78.1    18.3   77.9    24.9   0.5095
  VO~2~max \[ml/min/kg\]      213              16.4      3.6         16.1    4.4    209   16.4    3.5    16.3    4.6    0.8731
  E/e\' (medial)              213              12.7      3.6         11.9    4.3    209   12.8    4.4    11.9    3.6    0.6252
  log10NTproBNP               204              2.2       0.5         2.3     0.6    195   2.2     0.4    2.2     0.5    0.5052
  LAVI \[ml/m^2^\]            212              28.2      9.1         26.4    10.4   208   27.8    7.7    26.7    9.7    0.9586
  LVMI \[ml/m^2^\]            212              107.9     29.2        106.8   29.8   209   109.3   26.8   107.4   35.8   0.5347
  Hb \[g/dl\]                 213              13.8      1.2         13.8    1.5    209   13.8    1.3    13.8    1.8    0.8135
  VACI                        206              0.5       0.7         0.5     0.3    202   0.5     0.3    0.5     0.2    *0.0849*

Values in italic are smaller than 0.2, selection criterion before multiple regression model

BMI: body mass index; ECG: electrocardiogram; eGFR: estimated glomerular filtration rate; HR: heart rate; IQR: interquartile range; LAVI: left atrial volume indexed to body surface area; LVMI left ventricular mass indexed to body surface area; MAP :mean arterial pressure; SD: standard deviation; VACI: Ventricular‐atrial Coupling Index; VO~2~max: maximal oxygen uptake

Costs per item: physician visits and hospitalizations {#ehf212606-sec-0013}
-----------------------------------------------------

Because most data were collected in 2011, that year was also set as the reference point of time for all calculations.

The latest costs per outpatient physician visit given by the German physician\'s association were from 1999. We adjusted those values for inflation in 2011 and calculated 19.95 € per visit to the general practitioner and 71.16€ per visit to the cardiologist.

The average diagnosis‐related group‐based cost was 3168.03 € per hospitalization. We calculated additional 64.43 € per day in hospital for infrastructural costs. For rehabilitation, we calculated additional 121.12 € per day.

Overall direct cost {#ehf212606-sec-0014}
-------------------

As shown in [*Figure1*](#ehf212606-fig-0001){ref-type="fig"}, the overall direct costs are the sum of the costs for outpatient physician visits, hospitalization, rehabilitation, and medication. The mean overall cost per patient was 1188€. The median cost was in contrast 332€ as a result of most patients contributing to less than 1000€ per patient per year. The main component was hospitalization due to HF.

![Distribution of mean overall direct costs of the complete study population. Con‐medication: medication taken besides study drug (spironolactone/placebo); cardiologist: outpatient visits to cardiologist; GP: outpatient visits to general practitioner; hospitalization: hospitalization due to heart failure (HF); rehabilitation: rehabilitation due to HF.](EHF2-7-786-g001){#ehf212606-fig-0001}

Hospitalization and rehabilitation {#ehf212606-sec-0015}
----------------------------------

Because only 14.7% (62/422) of all subjects were hospitalized during the follow‐up period, its contribution to the overall costs of the investigated HFpEF cohort was very limited. However, for patients who were hospitalized, hospitalization was the most expensive item. This resulted in 640.7€ \[SD: ±1995.7€, median 0€ (Q~1~: 0€; Q~3~: 0€)\] average costs for hospitalization per study subject during the 12 months of follow‐up.

The same applies to patients who were admitted to rehabilitation and their costs. 5.5% (23/422) of subjects had at least one admission for rehabilitation care that generated an average cost of 122.3€ \[SD: ±693.3€, median 0€ (Q~1~: 0€; Q~3~: 0€)\] per rehabilitation treatment per patient annually.

Outpatient visits {#ehf212606-sec-0016}
-----------------

Among patients who were not hospitalized, outpatient visits, either to the cardiologist or the GP, were the most relevant cost item besides the prescribed medication.

One‐third of the study population had no visit to the GP during the follow‐up period. Seventy‐five percent of patients had up to two visits, and one patient was outlying with 48 GP visits during the follow‐up period. Thus, on average, 35.3€ \[SD: ±67.9, median 20€ (Q~1~: 0€; Q~3~: 40€)\] was spent for GP visits per patient during the follow‐up period.

Visits to the cardiologist were noticeably fewer but with a similar pattern. Seventy‐five percent of the study population had up to one visit to the cardiologist. The subject with the most visits to the cardiologist during the follow‐up had 10 visits. In total, visits to the cardiologist added up to an average cost of 31.2€ \[SD: ±68.5€, median 0€ (Q~1~: 0€; Q~3~: 71€)\] per patient during the follow‐up period.

Medication {#ehf212606-sec-0017}
----------

Considering the follow‐up visits at 3, 6, 9, and 12 months, about 29% of subjects on average reported altered medication and 66.1% (279/422) reported none or one change in medication during the complete follow‐up period. The con‐medication taken from all participants is shown in *Table* [3](#ehf212606-tbl-0003){ref-type="table"}.

###### 

Absolute and relative frequency of medication groups in both treatment arms

  Medication group                        Spironolactone (*n* = 213)   Placebo (*n* = 209)         
  --------------------------------------- ---------------------------- --------------------- ----- ----
  Antiarrhythmic agents                   12                           6                     21    10
  Beta blockers                           150                          70                    160   77
  CCB                                     47                           22                    74    35
  ACE inhibitors                          103                          48                    92    44
  ARBs                                    85                           40                    80    38
  Loop diuretics                          46                           22                    27    13
  Other diuretics                         97                           46                    99    47
  Nitrates                                23                           11                    18    9
  Cardiac glycosides                      4                            2                     4     2
  Statins                                 117                          55                    119   57
  Other cholesterol‐lowering medication   19                           9                     15    7
  Anticoagulants                          132                          62                    119   57
  Oral antidiabetic medication            30                           14                    20    10
  Pulmonary medication                    13                           6                     9     4
  Insulins                                4                            2                     11    5
  Antidepressants                         21                           10                    16    8

Mediation group was considered positive, when at least one drug from a medication group was reported to be part of the taken by patient at one of the study visits.

ACE: angiotensin‐converting‐enzyme inhibitor; anticoagulants: including antiplatelet therapy; ARBs: Angiotensin II receptor blockers; CCB: calcium channel blockers; Rel.: relative frequency.

Some of the frequently taken drugs created low median costs, like beta‐blockers (17€) and statins (23€). Some of the less frequently taken drug groups generated higher median costs, like antiarrhythmic agents (1313.6 €) and antidepressants (1894.9€). Anticoagulation, which included antiplatelet therapy in our analysis, was frequently taken and contributed notably to the costs with a relatively high median cost (1109.5€). These findings resulted in median con‐medication costs of 223€ per subject per year. The large distribution lead to nearly 100 subjects (one quartile) with costs less than 100 € and a quartile with costs more than 487€ per patient per year. These results are accompanied by mean costs of 358.7€ (SD: ±396.5) per patient per year.

Effect of spironolactone {#ehf212606-sec-0018}
------------------------

The costs for outpatient visits to both the GP and the cardiologist, the hospitalizations, and rehabilitation care were not different in the two study arms. *Table* [4](#ehf212606-tbl-0004){ref-type="table"} shows the distribution in the total patient cohort.

###### 

Comparison of the descriptive cost items without medication costs

  Cost item         Total patient cohort (*n* = 422)                     
  ----------------- ---------------------------------- -------- ---- --- ----
  GP                0                                  958      20   0   40
  Cardiologist      0                                  712      0    0   71
  Hospitalization   0                                  18,288   0    0   0
  Rehabilitation    0                                  8,478    0    0   0

Costs in € (Euro).

GP, costs of outpatient visits to the general practitioner; cardiologist, costs of outpatient visits to the cardiologist; hospitalization, costs of hospitalizations due to heart failure; rehabilitation, costs of rehabilitation care due to heart failure.

The medication costs between both treatment arms are not relevantly different (*P* = 0.84). Certain medication groups were different between these study arms but had no impact on the overall costs \[calcium channel blockers were taken more often in the placebo group (*P* = 0.01) and loop diuretics more in the spironolactone group (*P* = 0.02)\].

Predictors {#ehf212606-sec-0019}
----------

Factors associated with impact on the costs are shown in *Table* [5](#ehf212606-tbl-0005){ref-type="table"}. Factors like atrial fibrillation, coronary artery disease, and higher HF functional class were associated with higher costs, while higher haemoglobin levels in women predicted lower costs. Other factors, for example, age, arterial hypertension, and chronic obstructive pulmonary disease, as well as the level of diastolic dysfunction (E/e\'), showed no impact on higher costs.

###### 

Incidence rate ratio of relevant predictive factors for overall costs

  Predictive factor                 IRR     95% CI         *P*
  --------------------------------- ------- -------------- ---------
  Haemoglobin                       0.791   0.706--0.887   \<0.001
  VO~2~max                          1.049   1.009--1.090   0.015
  Female vs. male                   0.619   0.464--0.824   0.001
  CAD, yes vs. no                   1.399   1.026--1.910   0.034
  Hyperlipidaemia, yes vs. no       1.608   1.189--2.175   0.002
  Atrial fibrillation, yes vs. no   2.164   1.516--3.093   \<0.001
  NYHA III vs. II                   1.640   1.120--2.406   0.011

CAD: coronary artery disease; CI: confidence interval; IRR: incidence rate ratio; NYHA: New York Heart Association.

Discussion {#ehf212606-sec-0020}
==========

In this analysis, we measure for the first time the costs of an ambulatory HFpEF cohort, which account for a median amount of 332 € per patient per year (1118€ on average). The analysis of the structure revealed hospitalization as the driving cost factor followed by medication, rehabilitation, and outpatient visits. Spironolactone did not change the overall costs or the distribution over the different items; however, it showed associations with certain compositions of the con‐medication. Independent predictors for higher costs included men with lower haemoglobin values, better VO~2~max, as well as the presence of coronary artery disease, hyperlipidaemia, and atrial fibrillation.

This analysis gained power through the bottom‐up‐approach, which focused on the use of resources on every level of each subject instead of referring to aggregated cohort data.

Analyses by other authors investigating HF populations and providing their use of medical resources focused mainly on a different selection of patients, for example, Biermann *et al*. investigated a pooled HF cohort with LVEF \< 50%.[25](#ehf212606-bib-0025){ref-type="ref"} In that analysis, HFrEF and HF with mid‐range ejection fraction patients showed higher need for medical resources indicating higher costs. There were more often outpatient visits to both GPs as well as cardiologists than in our cohort \[6.1 (±9) and 1.7 (±2.5) vs. 1.8 (±3.4) and 0.4 (±1.0) per year\]. Hospital admissions due to HF were more frequent in those patients \[0.8 (±1.2) vs. 0.2 (±0.6) per year\]. However, even the basic characteristics differed: the cohort was younger and there were more male subjects \[25.2% female subjects and mean age 62.9 (± 13.6) years vs. 52% female subjects and mean age 67 (± 8) years\]. Both analyses, theirs and ours, could show that higher HF functional classes were associated with higher costs.

Focusing on HFpEF populations only, similar effects could be shown, for example, by Redfield *et al*. In the RELAX trial, they investigated the effect of phosphodiesterase‐5 inhibition with administration of sildenafil for 24 weeks, compared with placebo in an HFpEF cohort.[26](#ehf212606-bib-0026){ref-type="ref"} It did not result in significant improvement in exercise capacity or clinical status, but the data could be analysed in the same bottom‐up‐approach like ours and showed also a significant higher need for medical resources in both medication and hospitalization terms. Although the RELAX cohort was similar to the ALDO cohort regarding the basic baseline characteristics (mean age 69 years, 49% women), they differed in others, such as the comorbidities. In summary, comorbidities were more present in the RELAX than in the ALDO group, for example, arterial hypertension 85% vs. 92%, diabetes mellitus 43% vs. 17%, chronic obstructive pulmonary disease 19% vs. 3%, and atrial fibrillation 51% vs. 15%. Consequently, the number of con‐medication was higher than in the ALDO cohort, for example, loop diuretics 77% vs. 17% or ACEi 70% vs. 46%. Even in laboratory and clinical testing, the RELAX group appeared to be sicker with median N‐terminal pro brain natriuretic peptide values around 700 pg/mL vs. 158 pg/mL in the ALDO cohort. VO~2~max was at 11.7 mL/min/kg vs. \>16 mL/min/kg in the aldo‐DHF data. Diastolic parameters like E/e\' (16 vs. 11.8) and left atrial volume indexed to body surface area (44 mL/m^2^ vs. 26 mL/m^2^) were also different. This constellation indicates that patients with a higher disease burden have higher costs, represented by the fact that HF hospitalization was an inclusion criterion in RELAX but not in aldo‐DHF. In contrast, only 37% of aldo‐DHF patients had a hospitalization before baseline. Korves *et al*.[27](#ehf212606-bib-0027){ref-type="ref"} could show that hospitalization and especially the 6 months after HF hospitalization are the most costly periods of the patient journey.

Conclusively, we show that early stage HFpEF patients have lower costs and because managing the comorbidities is the main treatment approach at the moment, an early diagnosis and prevention as well as treatment of comorbidities reduces the economic costs even of an oligosymptomatic, relatively young HFpEF cohort.

In analysing the predictive factors for higher costs, the only item that we can change and improve besides optimal therapy of comorbidities is VO~2~max. This underlines the idea that physical exercises could improve HFpEF population outcomes and lower the costs of their care.

Limitations to this analysis include focusing on direct costs. Indirect costs, for example, disability to work, early retirement, and commute to diagnosis or treatment, were not included. Incidental costs in an elderly population with HFpEF are negligible due to their higher age (67 ± 8 years) and the presumed retirement. Intangible costs were not observed in the study protocol.

Compared with many other studies focusing on HFpEF, our study population is relatively young. Being young and only oligosymptomatic with a relatively low rate of HF hospitalization created lower costs.

But even the number of outpatient visits was much lower than expected, especially regarding visits to the cardiologist. Regular study visits may have influenced the number of other outpatient visits to the GP or cardiologist although subjects were instructed to keep regular appointments, including those required for prescriptions for the con‐medication.

Regarding the con‐medication, we most likely underestimate the real costs because we always calculated for the cheapest generic per largest pack size drug of an agent. At the same time, we only calculated single medication therapies and did not include polypills, which are usually cheaper than the combination of two drugs.

We could calculate the costs of a stable, oligosymptomatic patient with HFpEF per year. Because the hospitalizations and the following patient monitoring create the highest costs, we need to find methods to reduce HF hospitalizations and processes to decrease their impact on the overall costs in future steps.
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